Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review.

Clinical lung cancer - 1 Nov 2016

Sheikine Yuri, Rangachari Deepa, McDonald Danielle C, Huberman Mark S, Folch Erik S, VanderLaan Paul A, Costa Daniel B

Abstract excerpt

Expert consensus guidelines have defined minimum requirements for routine testing and identification of classical epidermal growth factor (EGFR) mutations (ie, exon 19 deletions and exon 21 L858R substitution) and anaplastic lymphoma kinase (ALK) rearrangements in advanced non-small-cell lung cancers of adenocarcinoma histology, with the intent of permitting use of these predictive biomarkers to select patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Mutation

Share to Precision Medicine

Share to Predictive Value of Tests

Source

Identifiers

PMID: 27381270
DOI: 10.1016/j.cllc.2016.05.016

Genes

EGFR
ALK

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review.PMID 27381270Read ↗

EGFR mutation testing in non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC.Semantic proximity Read ↗

EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer: Current Treatment Landscape and Future Directions.Semantic proximity Read ↗

Update on EGFR Mutational Testing and the Potential of Noninvasive Liquid Biopsy in Non-Small-cell Lung Cancer.Semantic proximity Read ↗

Current management of uncommon EGFR mutations in non-small cell lung cancer.Semantic proximity Read ↗

Large-Scale EGFR Mutation Testing in Clinical Practice: Analysis of a Series of 18,920 Non-Small Cell Lung Cancer Cases.Semantic proximity Read ↗

Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations.Semantic proximity Read ↗

Prevalence and Clinical Implications of Somatic and Germline EGFR Mutations in Patients with Non-Small Cell Lung CancerSemantic proximity Read ↗

Epidermal growth factor receptor mutation testing: From conventional to real-time diagnosis of lung cancer.Semantic proximity Read ↗

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.Semantic proximity Read ↗

Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision.Semantic proximity Read ↗

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.